Human PilotPubMed ID: 11700589·2001
Pharmacokinetics and Bioavailability of AOD 9604 in Healthy Subjects
Wallace JD, Cuneo RC, Lundqvist G, et al.
Journal of Clinical Pharmacology, 2001 · n = 34
Key finding
AOD 9604 peak levels at 30-60 minutes; half-life 3.1 hours; 73% bioavailability via subcutaneous injection.
Summary
Pharmacokinetic study establishing AOD 9604 peak plasma levels, elimination half-life, and subcutaneous bioavailability.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on AOD-9604
A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjects
Journal of Obesity & Weight Loss Therapy · 2013 · Human RCT
AOD 9604 Effects on Body Composition and Metabolic Parameters in Overweight Individuals with Type 2 Diabetes
Peptides · 2011 · Human RCT
Cartilage Protective Effects of AOD 9604 in Transgenic Mice with Accelerated Osteoarthritis
Osteoarthritis and Cartilage · 2010 · Animal Study
AOD 9604 Reduces Leptin Levels and Improves Leptin Sensitivity in High-Fat Diet Obese Rats
Diabetes · 2009 · Animal Study
AOD 9604 and Articular Cartilage Repair: Assessment in a Rat Cartilage Defect Model
Journal of Orthopaedic Research · 2008 · Animal Study